Bergamini A et al. |
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. |
2016 |
Expert Opin Investig Drugs |
pmid:27797594
|
Zhong P et al. |
Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. |
2016 |
Biomacromolecules |
pmid:27723970
|
Le QA et al. |
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. |
2016 |
Breast Cancer Res. Treat. |
pmid:27572338
|
Eckelmann D et al. |
Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. |
2016 |
Fitoterapia |
pmid:27521896
|
Jerjian TV et al. |
Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. |
2016 |
Pharmacotherapy |
pmid:26799352
|
Heudi O et al. |
Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. |
2016 |
J Pharm Biomed Anal |
pmid:26771131
|
de Vries CL et al. |
Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. |
2016 |
J. Neurooncol. |
pmid:26732082
|
Elsada A et al. |
NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. |
2016 |
Lancet Oncol. |
pmid:26703893
|
Luo Q et al. |
Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. |
2016 |
Anal. Chem. |
pmid:26629796
|
Gebhart G et al. |
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. |
2016 |
Ann. Oncol. |
pmid:26598545
|
Fan Y et al. |
Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum. |
2016 |
Appl. Microbiol. Biotechnol. |
pmid:26585444
|
Baselga J et al. |
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. |
2016 |
Clin. Cancer Res. |
pmid:26920887
|
Force J et al. |
Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. |
2016 |
J. Clin. Oncol. |
pmid:24778392
|
Ponte JF et al. |
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. |
2016 |
Neoplasia |
pmid:27889646
|
Hassan R et al. |
Mesothelin Immunotherapy for Cancer: Ready for Prime Time? |
2016 |
J. Clin. Oncol. |
pmid:27863199
|
Kim SB et al. |
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. |
2016 |
Int. J. Cancer |
pmid:27428671
|
Mitsuya K et al. |
Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. |
2016 |
BMC Cancer |
pmid:27377061
|
Cilliers C et al. |
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. |
2016 |
AAPS J |
pmid:27287046
|
Martin M and López-Tarruella S |
Emerging Therapeutic Options for HER2-Positive Breast Cancer. |
2016 |
Am Soc Clin Oncol Educ Book |
pmid:27249772
|
Singh R et al. |
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. |
2016 |
Mol. Cancer Ther. |
pmid:27197308
|